JP2014504300A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014504300A5 JP2014504300A5 JP2013546075A JP2013546075A JP2014504300A5 JP 2014504300 A5 JP2014504300 A5 JP 2014504300A5 JP 2013546075 A JP2013546075 A JP 2013546075A JP 2013546075 A JP2013546075 A JP 2013546075A JP 2014504300 A5 JP2014504300 A5 JP 2014504300A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- imidazole
- indene
- dispiro
- amine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 62
- 125000000217 alkyl group Chemical group 0.000 claims 54
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 27
- 229910052736 halogen Inorganic materials 0.000 claims 25
- 150000002367 halogens Chemical class 0.000 claims 25
- 125000001072 heteroaryl group Chemical group 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 21
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 20
- 125000004093 cyano group Chemical group *C#N 0.000 claims 19
- 125000003118 aryl group Chemical group 0.000 claims 14
- 125000001424 substituent group Chemical group 0.000 claims 12
- -1 OR 8 Chemical group 0.000 claims 11
- 125000000623 heterocyclic group Chemical group 0.000 claims 11
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 9
- 125000001188 haloalkyl group Chemical group 0.000 claims 8
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 7
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 claims 7
- 208000024827 Alzheimer disease Diseases 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 4
- XCUAIINAJCDIPM-XVFCMESISA-N N(4)-hydroxycytidine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=NO)C=C1 XCUAIINAJCDIPM-XVFCMESISA-N 0.000 claims 4
- 125000002877 alkyl aryl group Chemical group 0.000 claims 4
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 4
- 125000002619 bicyclic group Chemical group 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 4
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 230000007170 pathology Effects 0.000 claims 3
- 125000003367 polycyclic group Chemical group 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- NNEAKBWZBQOQDH-UHFFFAOYSA-N 3-(1h-inden-2-yl)pyridine Chemical compound C=1C2=CC=CC=C2CC=1C1=CC=CN=C1 NNEAKBWZBQOQDH-UHFFFAOYSA-N 0.000 claims 1
- XSQKUWZLKKUZPU-UHFFFAOYSA-N 3-(4''-amino-5''-methyl-3'h-dispiro[cyclopropane-1,2'-indene-1',2''-imidazol]-6'-yl)-5-chlorobenzonitrile Chemical compound N1=C(N)C(C)=NC21C1(CC1)CC1=CC=C(C=3C=C(C=C(Cl)C=3)C#N)C=C12 XSQKUWZLKKUZPU-UHFFFAOYSA-N 0.000 claims 1
- VOAYXBVNQZNDJQ-UHFFFAOYSA-N 4-methoxy-5''-methyl-6'-[4-methyl-5-(prop-1-yn-1-yl)pyridin-3-yl]-3'h-dispiro[cyclohexane-1,2'-indene-1',2''-imidazol]-4''-amine Chemical compound C1CC(OC)CCC11C2(N=C(N)C(C)=N2)C2=CC(C=3C(=C(C#CC)C=NC=3)C)=CC=C2C1 VOAYXBVNQZNDJQ-UHFFFAOYSA-N 0.000 claims 1
- AMESWUXBYLEHJV-UHFFFAOYSA-N 6'-(3-chloro-4-fluorophenyl)-5-methyl-5'',6''-dihydro-4''h-dispiro[imidazole-2,4'-chromene-2',3''-pyran]-4-amine Chemical compound N1=C(N)C(C)=NC11C2=CC(C=3C=C(Cl)C(F)=CC=3)=CC=C2OC2(COCCC2)C1 AMESWUXBYLEHJV-UHFFFAOYSA-N 0.000 claims 1
- NDUICAHCFCQKCR-UHFFFAOYSA-N 6'-(3-chlorophenyl)-5-methyl-5'',6''-dihydro-4''h-dispiro[imidazole-2,4'-chromene-2',3''-pyran]-4-amine Chemical compound N1=C(N)C(C)=NC11C2=CC(C=3C=C(Cl)C=CC=3)=CC=C2OC2(COCCC2)C1 NDUICAHCFCQKCR-UHFFFAOYSA-N 0.000 claims 1
- MKLSHCVZEOAEFB-UHFFFAOYSA-N 6'-(5-chloropyridin-3-yl)-5''-methyl-3'h-dispiro[cyclobutane-1,2'-indene-1',2''-imidazol]-4''-amine Chemical class N1=C(N)C(C)=NC21C1(CCC1)CC1=CC=C(C=3C=C(Cl)C=NC=3)C=C12 MKLSHCVZEOAEFB-UHFFFAOYSA-N 0.000 claims 1
- UAEMPXBCTYCXDD-UHFFFAOYSA-N 6'-(cyclopropylethynyl)-5''-methyl-3'h-dispiro[cyclobutane-1,2'-indene-1',2''-imidazol]-4''-amine Chemical compound N1=C(N)C(C)=NC21C1(CCC1)CC1=CC=C(C#CC3CC3)C=C12 UAEMPXBCTYCXDD-UHFFFAOYSA-N 0.000 claims 1
- SEMLTECGFLAMPC-UHFFFAOYSA-N 6'-bromo-4-(difluoromethyl)-5''-methyl-3'h-dispiro[cyclohexane-1,2'-indene-1',2''-imidazol]-4''-amine Chemical compound N1=C(N)C(C)=NC21C1(CCC(CC1)C(F)F)CC1=CC=C(Br)C=C12 SEMLTECGFLAMPC-UHFFFAOYSA-N 0.000 claims 1
- NYMXIKPEDWDOQL-UHFFFAOYSA-N 6'-bromo-4-methoxy-5''-methyl-3'h-dispiro[cyclohexane-1,2'-indene-1',2''-imidazol]-4''-amine Chemical compound C1CC(OC)CCC11C2(N=C(N)C(C)=N2)C2=CC(Br)=CC=C2C1 NYMXIKPEDWDOQL-UHFFFAOYSA-N 0.000 claims 1
- VPPGDUMXGIDOQT-UHFFFAOYSA-N 6'-bromo-5''-methyl-3'h-dispiro[cyclobutane-1,2'-indene-1',2''-imidazol]-4''-amine Chemical compound N1=C(N)C(C)=NC21C1(CCC1)CC1=CC=C(Br)C=C12 VPPGDUMXGIDOQT-UHFFFAOYSA-N 0.000 claims 1
- DFCZJGXXKNWQJL-UHFFFAOYSA-N 6'-bromo-5''-methyl-3'h-dispiro[cyclopropane-1,2'-indene-1',2''-imidazol]-4''-amine Chemical compound N1=C(N)C(C)=NC21C1(CC1)CC1=CC=C(Br)C=C12 DFCZJGXXKNWQJL-UHFFFAOYSA-N 0.000 claims 1
- NTHHXIKGFGHHJO-UHFFFAOYSA-N 6'-bromo-5''-methyl-4-(trifluoromethyl)-3'h-dispiro[cyclohexane-1,2'-indene-1',2''-imidazol]-4''-amine Chemical compound N1=C(N)C(C)=NC21C1(CCC(CC1)C(F)(F)F)CC1=CC=C(Br)C=C12 NTHHXIKGFGHHJO-UHFFFAOYSA-N 0.000 claims 1
- OQJQQWGZYQBQJI-UHFFFAOYSA-N 6'-bromo-5-methyl-2'',3'',5'',6''-tetrahydro-3'h-dispiro[imidazole-2,1'-indene-2',4''-pyran]-4-amine Chemical compound N1=C(N)C(C)=NC21C1(CCOCC1)CC1=CC=C(Br)C=C12 OQJQQWGZYQBQJI-UHFFFAOYSA-N 0.000 claims 1
- IDOTUYBHWAHCGP-UHFFFAOYSA-N 6'-bromo-5-methyl-5'',6''-dihydro-4''h-dispiro[imidazole-2,4'-chromene-2',3''-pyran]-4-amine Chemical compound N1=C(N)C(C)=NC11C2=CC(Br)=CC=C2OC2(COCCC2)C1 IDOTUYBHWAHCGP-UHFFFAOYSA-N 0.000 claims 1
- NMPGDLCHDFBBBC-UHFFFAOYSA-N 6-(2,3-difluorophenyl)-5'-methylspiro[2,3-dihydrochromene-4,2'-imidazole]-4'-amine Chemical compound N1=C(N)C(C)=NC11C2=CC(C=3C(=C(F)C=CC=3)F)=CC=C2OCC1 NMPGDLCHDFBBBC-UHFFFAOYSA-N 0.000 claims 1
- OOCXJKMXIADCPK-UHFFFAOYSA-N 6-(2,5-dimethoxyphenyl)-5'-methylspiro[2,3-dihydrochromene-4,2'-imidazole]-4'-amine Chemical compound COC1=CC=C(OC)C(C=2C=C3C4(N=C(N)C(C)=N4)CCOC3=CC=2)=C1 OOCXJKMXIADCPK-UHFFFAOYSA-N 0.000 claims 1
- ASTARQOFIHHADR-UHFFFAOYSA-N 6-(2,5-dimethylphenyl)-5'-methylspiro[2,3-dihydrochromene-4,2'-imidazole]-4'-amine Chemical compound N1=C(N)C(C)=NC11C2=CC(C=3C(=CC=C(C)C=3)C)=CC=C2OCC1 ASTARQOFIHHADR-UHFFFAOYSA-N 0.000 claims 1
- HZUBJQJZQJTUIS-UHFFFAOYSA-N 6-(2-fluoro-3-methoxyphenyl)-5'-methylspiro[2,3-dihydrochromene-4,2'-imidazole]-4'-amine Chemical compound COC1=CC=CC(C=2C=C3C4(N=C(N)C(C)=N4)CCOC3=CC=2)=C1F HZUBJQJZQJTUIS-UHFFFAOYSA-N 0.000 claims 1
- RSJMUFIUQMEIDV-UHFFFAOYSA-N 6-(2-fluoro-5-methoxyphenyl)-5'-methylspiro[2,3-dihydrochromene-4,2'-imidazole]-4'-amine Chemical compound COC1=CC=C(F)C(C=2C=C3C4(N=C(N)C(C)=N4)CCOC3=CC=2)=C1 RSJMUFIUQMEIDV-UHFFFAOYSA-N 0.000 claims 1
- MJCNDWZEGNXOEP-UHFFFAOYSA-N 6-(2-fluoro-5-methylphenyl)-5'-methylspiro[2,3-dihydrochromene-4,2'-imidazole]-4'-amine Chemical compound N1=C(N)C(C)=NC11C2=CC(C=3C(=CC=C(C)C=3)F)=CC=C2OCC1 MJCNDWZEGNXOEP-UHFFFAOYSA-N 0.000 claims 1
- SVICWOABALJMFD-UHFFFAOYSA-N 6-(2-methoxy-5-methylphenyl)-5'-methylspiro[2,3-dihydrochromene-4,2'-imidazole]-4'-amine Chemical compound COC1=CC=C(C)C=C1C1=CC=C(OCCC23N=C(N)C(C)=N3)C2=C1 SVICWOABALJMFD-UHFFFAOYSA-N 0.000 claims 1
- BTQYJGMMVLMRIM-UHFFFAOYSA-N 6-(3,5-dichlorophenyl)-5'-methylspiro[2,3-dihydrochromene-4,2'-imidazole]-4'-amine Chemical compound N1=C(N)C(C)=NC11C2=CC(C=3C=C(Cl)C=C(Cl)C=3)=CC=C2OCC1 BTQYJGMMVLMRIM-UHFFFAOYSA-N 0.000 claims 1
- XPBCXYLXDCQPPG-UHFFFAOYSA-N 6-(3,5-difluorophenyl)-5'-methylspiro[2,3-dihydrochromene-4,2'-imidazole]-4'-amine Chemical compound N1=C(N)C(C)=NC11C2=CC(C=3C=C(F)C=C(F)C=3)=CC=C2OCC1 XPBCXYLXDCQPPG-UHFFFAOYSA-N 0.000 claims 1
- XVHSHDMIBQAYGQ-UHFFFAOYSA-N 6-(3,5-dimethylphenyl)-5'-methylspiro[2,3-dihydrochromene-4,2'-imidazole]-4'-amine Chemical compound N1=C(N)C(C)=NC11C2=CC(C=3C=C(C)C=C(C)C=3)=CC=C2OCC1 XVHSHDMIBQAYGQ-UHFFFAOYSA-N 0.000 claims 1
- PNGMSULGCSIWPT-UHFFFAOYSA-N 6-(3-chlorophenyl)-2-(2,2-dimethyloxan-4-yl)-5'-methylspiro[2,3-dihydrochromene-4,2'-imidazole]-4'-amine Chemical compound N1=C(N)C(C)=NC11C2=CC(C=3C=C(Cl)C=CC=3)=CC=C2OC(C2CC(C)(C)OCC2)C1 PNGMSULGCSIWPT-UHFFFAOYSA-N 0.000 claims 1
- MWVBEWBNSOHPSD-UHFFFAOYSA-N 6-(3-chlorophenyl)-5'-methyl-2-(oxan-3-yl)spiro[2,3-dihydrochromene-4,2'-imidazole]-4'-amine Chemical compound N1=C(N)C(C)=NC11C2=CC(C=3C=C(Cl)C=CC=3)=CC=C2OC(C2COCCC2)C1 MWVBEWBNSOHPSD-UHFFFAOYSA-N 0.000 claims 1
- ULLKDRHZBXMQBC-UHFFFAOYSA-N 6-(5-chloropyridin-3-yl)-5'-methylspiro[2,3-dihydro-1h-naphthalene-4,2'-imidazole]-4'-amine Chemical compound N1=C(N)C(C)=NC11C2=CC(C=3C=C(Cl)C=NC=3)=CC=C2CCC1 ULLKDRHZBXMQBC-UHFFFAOYSA-N 0.000 claims 1
- XNFNZERRRUIVBJ-UHFFFAOYSA-N 6-(5-chloropyridin-3-yl)-5'-methylspiro[2,3-dihydrochromene-4,2'-imidazole]-4'-amine Chemical compound N1=C(N)C(C)=NC11C2=CC(C=3C=C(Cl)C=NC=3)=CC=C2OCC1 XNFNZERRRUIVBJ-UHFFFAOYSA-N 0.000 claims 1
- PVASJWZFVWATEB-UHFFFAOYSA-N 6-(5-fluoro-2-methoxyphenyl)-5'-methylspiro[2,3-dihydrochromene-4,2'-imidazole]-4'-amine Chemical compound COC1=CC=C(F)C=C1C1=CC=C(OCCC23N=C(N)C(C)=N3)C2=C1 PVASJWZFVWATEB-UHFFFAOYSA-N 0.000 claims 1
- IBGZXUPONLUVLS-UHFFFAOYSA-N 6-bromo-2-(2,2-dimethyloxan-4-yl)-5'-methylspiro[2,3-dihydrochromene-4,2'-imidazole]-4'-amine Chemical compound N1=C(N)C(C)=NC11C2=CC(Br)=CC=C2OC(C2CC(C)(C)OCC2)C1 IBGZXUPONLUVLS-UHFFFAOYSA-N 0.000 claims 1
- ONKRKKQEVGYQDK-UHFFFAOYSA-N 6-bromo-5'-methyl-2-(oxan-3-yl)spiro[2,3-dihydrochromene-4,2'-imidazole]-4'-amine Chemical compound N1=C(N)C(C)=NC11C2=CC(Br)=CC=C2OC(C2COCCC2)C1 ONKRKKQEVGYQDK-UHFFFAOYSA-N 0.000 claims 1
- QNHHDQXBRHSEHK-UHFFFAOYSA-N 6-bromo-5'-methylspiro[2,3-dihydro-1h-naphthalene-4,2'-imidazole]-4'-amine Chemical compound N1=C(N)C(C)=NC11C2=CC(Br)=CC=C2CCC1 QNHHDQXBRHSEHK-UHFFFAOYSA-N 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 1
- 206010059245 Angiopathy Diseases 0.000 claims 1
- PJFLXADHRCSJTF-UHFFFAOYSA-N C1CC(OC)(C)CCC11C2(N=C(N)C(C)=N2)C2=CC(C=3C=C(C=NC=3)C#CC)=CC=C2C1 Chemical compound C1CC(OC)(C)CCC11C2(N=C(N)C(C)=N2)C2=CC(C=3C=C(C=NC=3)C#CC)=CC=C2C1 PJFLXADHRCSJTF-UHFFFAOYSA-N 0.000 claims 1
- IBJMVRAGTMDAFC-UHFFFAOYSA-N C1CC(OC)CCC11C2(N=C(N)C(C)=N2)C2=CC(C#N)=CC=C2C1 Chemical compound C1CC(OC)CCC11C2(N=C(N)C(C)=N2)C2=CC(C#N)=CC=C2C1 IBJMVRAGTMDAFC-UHFFFAOYSA-N 0.000 claims 1
- MUPBWXCOUHZWEH-UHFFFAOYSA-N C1CC(OC)CCC11C2(N=C(N)C(C)=N2)C2=CC(C=3C(=C(OC)C=CC=3)F)=CC=C2C1 Chemical compound C1CC(OC)CCC11C2(N=C(N)C(C)=N2)C2=CC(C=3C(=C(OC)C=CC=3)F)=CC=C2C1 MUPBWXCOUHZWEH-UHFFFAOYSA-N 0.000 claims 1
- JJDMMVKGGCIWNE-UHFFFAOYSA-N C1CC(OC)CCC11C2(N=C(N)C(C)=N2)C2=CC(C=3C(=CC=C(OC)C=3)F)=CC=C2C1 Chemical compound C1CC(OC)CCC11C2(N=C(N)C(C)=N2)C2=CC(C=3C(=CC=C(OC)C=3)F)=CC=C2C1 JJDMMVKGGCIWNE-UHFFFAOYSA-N 0.000 claims 1
- UMCUVZSSUIPNCL-UHFFFAOYSA-N C1CC(OC)CCC11C2(N=C(N)C(C)=N2)C2=CC(C=3C=C(Br)C=NC=3)=CC=C2C1 Chemical compound C1CC(OC)CCC11C2(N=C(N)C(C)=N2)C2=CC(C=3C=C(Br)C=NC=3)=CC=C2C1 UMCUVZSSUIPNCL-UHFFFAOYSA-N 0.000 claims 1
- JXMIZSIVCHFRDW-UHFFFAOYSA-N C1CC(OC)CCC11C2(N=C(N)C(C)=N2)C2=CC(C=3C=C(C)C=NC=3)=CC=C2C1 Chemical compound C1CC(OC)CCC11C2(N=C(N)C(C)=N2)C2=CC(C=3C=C(C)C=NC=3)=CC=C2C1 JXMIZSIVCHFRDW-UHFFFAOYSA-N 0.000 claims 1
- YNWCSWFGCSURHN-UHFFFAOYSA-N C1CC(OC)CCC11C2(N=C(N)C(C)=N2)C2=CC(C=3C=C(C=CC=3)C#CC)=CC=C2C1 Chemical compound C1CC(OC)CCC11C2(N=C(N)C(C)=N2)C2=CC(C=3C=C(C=CC=3)C#CC)=CC=C2C1 YNWCSWFGCSURHN-UHFFFAOYSA-N 0.000 claims 1
- PBZIPKGPSVOZPH-UHFFFAOYSA-N C1CC(OC)CCC11C2(N=C(N)C(C)=N2)C2=CC(C=3C=C(COCC(F)(F)F)C=NC=3)=CC=C2C1 Chemical compound C1CC(OC)CCC11C2(N=C(N)C(C)=N2)C2=CC(C=3C=C(COCC(F)(F)F)C=NC=3)=CC=C2C1 PBZIPKGPSVOZPH-UHFFFAOYSA-N 0.000 claims 1
- RJIJEEIOHDLRFZ-UHFFFAOYSA-N C1CC(OC)CCC11C2(N=C(N)C(C)=N2)C2=CC(C=3C=C4C(C)=CNC4=CC=3)=CC=C2C1 Chemical compound C1CC(OC)CCC11C2(N=C(N)C(C)=N2)C2=CC(C=3C=C4C(C)=CNC4=CC=3)=CC=C2C1 RJIJEEIOHDLRFZ-UHFFFAOYSA-N 0.000 claims 1
- MQZGUSZHWAGWJN-UHFFFAOYSA-N C1CC(OC)CCC11C2(N=C(N)C(C)=N2)C2=CC(C=3C=C4C(C)=CNC4=NC=3)=CC=C2C1 Chemical compound C1CC(OC)CCC11C2(N=C(N)C(C)=N2)C2=CC(C=3C=C4C(C)=CNC4=NC=3)=CC=C2C1 MQZGUSZHWAGWJN-UHFFFAOYSA-N 0.000 claims 1
- BABSGYNDJJCRAD-UHFFFAOYSA-N C1CC(OC)CCC11C2(N=C(N)C(C)=N2)C2=CC(C=3C=CC=CC=3)=CC=C2C1 Chemical compound C1CC(OC)CCC11C2(N=C(N)C(C)=N2)C2=CC(C=3C=CC=CC=3)=CC=C2C1 BABSGYNDJJCRAD-UHFFFAOYSA-N 0.000 claims 1
- XWVPZETUJYENCA-UHFFFAOYSA-N C1CC(OC)CCC11C2(N=C(N)C(C)=N2)C2=CC(OCC3CCC3)=CC=C2C1 Chemical compound C1CC(OC)CCC11C2(N=C(N)C(C)=N2)C2=CC(OCC3CCC3)=CC=C2C1 XWVPZETUJYENCA-UHFFFAOYSA-N 0.000 claims 1
- BGVASHDMRXAQIW-UHFFFAOYSA-N C1CC(OCC)CCC11C2(N=C(N)C(C)=N2)C2=CC(Br)=CC=C2C1 Chemical compound C1CC(OCC)CCC11C2(N=C(N)C(C)=N2)C2=CC(Br)=CC=C2C1 BGVASHDMRXAQIW-UHFFFAOYSA-N 0.000 claims 1
- GOOGDNLQKOSOJY-UHFFFAOYSA-N C1CC(OCC)CCC11C2(N=C(N)C(C)=N2)C2=CC(C=3C=C(Cl)C=NC=3)=CC=C2C1 Chemical compound C1CC(OCC)CCC11C2(N=C(N)C(C)=N2)C2=CC(C=3C=C(Cl)C=NC=3)=CC=C2C1 GOOGDNLQKOSOJY-UHFFFAOYSA-N 0.000 claims 1
- FBRMBFBHYONUMR-UHFFFAOYSA-N C1CCC2(CC1)C3(C4=CC=CC=C4O2)N=CC(=N3)N Chemical compound C1CCC2(CC1)C3(C4=CC=CC=C4O2)N=CC(=N3)N FBRMBFBHYONUMR-UHFFFAOYSA-N 0.000 claims 1
- LJSQZUIHVXHZEP-UHFFFAOYSA-N CC=1C=NC2(CCCC3=CC=C(C=C23)C=2C=NC=C(C2)C#CC)N1 Chemical compound CC=1C=NC2(CCCC3=CC=C(C=C23)C=2C=NC=C(C2)C#CC)N1 LJSQZUIHVXHZEP-UHFFFAOYSA-N 0.000 claims 1
- OJULZIHGKOEUGD-UHFFFAOYSA-N COCC1=CC=CC(C=2C=C3C4(N=C(N)C(C)=N4)C4(CCC(CC4)OC)CC3=CC=2)=C1 Chemical compound COCC1=CC=CC(C=2C=C3C4(N=C(N)C(C)=N4)C4(CCC(CC4)OC)CC3=CC=2)=C1 OJULZIHGKOEUGD-UHFFFAOYSA-N 0.000 claims 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- BIODWENPZVUOJQ-UHFFFAOYSA-N N1=C(N)C(C)=NC21C1(CCC(CC1)OC(F)F)CC1=CC=C(Br)C=C12 Chemical compound N1=C(N)C(C)=NC21C1(CCC(CC1)OC(F)F)CC1=CC=C(Br)C=C12 BIODWENPZVUOJQ-UHFFFAOYSA-N 0.000 claims 1
- VABJLQOQMZEOHJ-UHFFFAOYSA-N N1=C(N)C(C)=NC21C1(CCC(CC1)OC(F)F)CC1=CC=C(C=3C=C(C=NC=3)C(F)(F)F)C=C12 Chemical compound N1=C(N)C(C)=NC21C1(CCC(CC1)OC(F)F)CC1=CC=C(C=3C=C(C=NC=3)C(F)(F)F)C=C12 VABJLQOQMZEOHJ-UHFFFAOYSA-N 0.000 claims 1
- KGNLPACQRCXMGM-UHFFFAOYSA-N N1=C(N)C(C)=NC21C1(CCC(CC1)OC(F)F)CC1=CC=C(C=3C=C(F)C=C(F)C=3)C=C12 Chemical compound N1=C(N)C(C)=NC21C1(CCC(CC1)OC(F)F)CC1=CC=C(C=3C=C(F)C=C(F)C=3)C=C12 KGNLPACQRCXMGM-UHFFFAOYSA-N 0.000 claims 1
- RZZDAMQILXHFNA-UHFFFAOYSA-N N1=C(N)C(CC)=NC21C1(CCC(CC1)OC)CC1=CC=C(Br)C=C12 Chemical compound N1=C(N)C(CC)=NC21C1(CCC(CC1)OC)CC1=CC=C(Br)C=C12 RZZDAMQILXHFNA-UHFFFAOYSA-N 0.000 claims 1
- QRKMJBIQBFXXFC-UHFFFAOYSA-N N1=C(N)C(CC)=NC21C1(CCC(CC1)OC)CC1=CC=C(C=3C=C(Cl)C=NC=3)C=C12 Chemical compound N1=C(N)C(CC)=NC21C1(CCC(CC1)OC)CC1=CC=C(C=3C=C(Cl)C=NC=3)C=C12 QRKMJBIQBFXXFC-UHFFFAOYSA-N 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010036631 Presenile dementia Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 210000004227 basal ganglia Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 1
- 239000002475 cognitive enhancer Substances 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- 238000010790 dilution Methods 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 150000002460 imidazoles Chemical class 0.000 claims 1
- LAQPNDIUHRHNCV-UHFFFAOYSA-N isophthalonitrile Chemical compound N#CC1=CC=CC(C#N)=C1 LAQPNDIUHRHNCV-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 239000003695 memory enhancer Substances 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- BRXHNDFMYDDAFF-UHFFFAOYSA-N n-(4'-amino-5'-methylspiro[2,3-dihydrochromene-4,2'-imidazole]-6-yl)-3,5-dichloropyridine-2-carboxamide Chemical compound N1=C(N)C(C)=NC11C2=CC(NC(=O)C=3C(=CC(Cl)=CN=3)Cl)=CC=C2OCC1 BRXHNDFMYDDAFF-UHFFFAOYSA-N 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 150000002825 nitriles Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- MWWATHDPGQKSAR-UHFFFAOYSA-N propyne Chemical compound CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- XSPYGYYSPGDIRH-UHFFFAOYSA-N us8865911, 20e Chemical compound C1CC(OC)CCC11C2(N=C(N)C(C)=N2)C2=CC(C=3C=C(Cl)C=NC=3)=CC=C2C1 XSPYGYYSPGDIRH-UHFFFAOYSA-N 0.000 claims 1
- IQIVZKLXTXCLSL-UHFFFAOYSA-N us8865911, 20f Chemical compound C1CC(OC)CCC11C2(N=C(N)C(C)=N2)C2=CC(C=3C=C(F)C=NC=3)=CC=C2C1 IQIVZKLXTXCLSL-UHFFFAOYSA-N 0.000 claims 1
- ZTHSMBOBTMQWJX-UHFFFAOYSA-N us8865911, 20i Chemical compound C1CC(OC)CCC11C2(N=C(N)C(C)=N2)C2=CC(C#CC3CC3)=CC=C2C1 ZTHSMBOBTMQWJX-UHFFFAOYSA-N 0.000 claims 1
- BQDUISPSAOQZDJ-UHFFFAOYSA-N us8865911, 20t Chemical compound C1CC(OC)CCC11C2(N=C(N)C(C)=N2)C2=CC(OCC(C)C)=CC=C2C1 BQDUISPSAOQZDJ-UHFFFAOYSA-N 0.000 claims 1
- JJEORDNWHQBLEW-UHFFFAOYSA-N us8865911, 20u Chemical compound C1CC(OC)CCC11C2(N=C(N)C(C)=N2)C2=CC(OCCC(F)(F)F)=CC=C2C1 JJEORDNWHQBLEW-UHFFFAOYSA-N 0.000 claims 1
- HKXVZYVBKHNCOB-UHFFFAOYSA-N us8865911, 20v Chemical compound C1CC(OC)CCC11C2(N=C(N)C(C)=N2)C2=CC(OCCCF)=CC=C2C1 HKXVZYVBKHNCOB-UHFFFAOYSA-N 0.000 claims 1
- XUWDIJDGYAIURP-UHFFFAOYSA-N us8865911, 26a Chemical compound N1=C(N)C(C)=NC21C1(CCOCC1)CC1=CC=C(C=3C=C(Cl)C=CC=3)C=C12 XUWDIJDGYAIURP-UHFFFAOYSA-N 0.000 claims 1
- YUFMOSSQCPKPCP-UHFFFAOYSA-N us8865911, 26c Chemical compound N1=C(N)C(C)=NC21C1(CCOCC1)CC1=CC=C(C=3C=C(Cl)C(F)=CC=3)C=C12 YUFMOSSQCPKPCP-UHFFFAOYSA-N 0.000 claims 1
- QYVNHRYCOVFLFE-UHFFFAOYSA-N us8865911, 28c Chemical compound N1=C(N)C(C)=NC21C1(CCC(F)(F)CC1)CC1=CC=C(C=3C=C(Cl)C=NC=3)C=C12 QYVNHRYCOVFLFE-UHFFFAOYSA-N 0.000 claims 1
- RVZQCFAUGDSGAA-UHFFFAOYSA-N us8865911, 30d Chemical compound C1CC(OC)CCC21C1(N=C(N)C(C)=N1)C1=CC(C=3C=C(Cl)C=NC=3)=CC=C1O2 RVZQCFAUGDSGAA-UHFFFAOYSA-N 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061425852P | 2010-12-22 | 2010-12-22 | |
| US61/425,852 | 2010-12-22 | ||
| US201161529620P | 2011-08-31 | 2011-08-31 | |
| US61/529,620 | 2011-08-31 | ||
| PCT/SE2011/051555 WO2012087237A1 (en) | 2010-12-22 | 2011-12-21 | Compounds and their use as bace inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016149234A Division JP6333317B2 (ja) | 2010-12-22 | 2016-07-29 | 化合物及びｂａｃｅ阻害剤としてのその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014504300A JP2014504300A (ja) | 2014-02-20 |
| JP2014504300A5 true JP2014504300A5 (https=) | 2015-01-08 |
| JP6180325B2 JP6180325B2 (ja) | 2017-08-16 |
Family
ID=46314249
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013546075A Active JP6180325B2 (ja) | 2010-12-22 | 2011-12-21 | 化合物及びｂａｃｅ阻害剤としてのその使用 |
| JP2016149234A Active JP6333317B2 (ja) | 2010-12-22 | 2016-07-29 | 化合物及びｂａｃｅ阻害剤としてのその使用 |
| JP2018011088A Expired - Fee Related JP6527255B2 (ja) | 2010-12-22 | 2018-01-26 | 化合物及びｂａｃｅ阻害剤としてのその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016149234A Active JP6333317B2 (ja) | 2010-12-22 | 2016-07-29 | 化合物及びｂａｃｅ阻害剤としてのその使用 |
| JP2018011088A Expired - Fee Related JP6527255B2 (ja) | 2010-12-22 | 2018-01-26 | 化合物及びｂａｃｅ阻害剤としてのその使用 |
Country Status (40)
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102812005B (zh) | 2010-02-24 | 2014-12-10 | 生命医药公司 | β-分泌酶抑制剂 |
| US8415483B2 (en) * | 2010-12-22 | 2013-04-09 | Astrazeneca Ab | Compounds and their use as BACE inhibitors |
| EP2780321B1 (en) | 2011-10-10 | 2015-12-30 | Astrazeneca AB | Mono-fluoro beta-secretase inhibitors |
| US8779355B2 (en) * | 2011-12-28 | 2014-07-15 | Quest Diagnostics Investments, Inc. | Methods for detecting lacosamide by mass spectrometry |
| UA113538C2 (xx) | 2012-01-26 | 2017-02-10 | Фторметил-5,6-дигідро-4h-$1,3]оксазини | |
| TWI557112B (zh) * | 2012-03-05 | 2016-11-11 | 百靈佳殷格翰國際股份有限公司 | β－分泌酶抑制劑 |
| JP2015518048A (ja) | 2012-05-30 | 2015-06-25 | コメンティス， インコーポレイテッド | クロマン化合物 |
| US9000182B2 (en) * | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | 2H-imidazol-4-amine compounds and their use as BACE inhibitors |
| US9000184B2 (en) * | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors |
| US9000183B2 (en) * | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors |
| US9000185B2 (en) * | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cycloalkyl ether compounds and their use as BACE inhibitors |
| US10548882B2 (en) * | 2012-06-21 | 2020-02-04 | Astrazeneca Ab | Camsylate salt |
| TW201422592A (zh) | 2012-08-27 | 2014-06-16 | Boehringer Ingelheim Int | β－分泌酶抑制劑 |
| JP2015532282A (ja) * | 2012-09-28 | 2015-11-09 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | β−セクレターゼの阻害剤 |
| US20140371283A1 (en) | 2013-02-12 | 2014-12-18 | Buck Institute For Research On Aging | Hydantoins that modulate bace-mediated app processing |
| TW201629025A (zh) | 2014-10-07 | 2016-08-16 | 阿斯特捷利康公司 | 化合物及其作為ｂａｃｅ抑制劑之用途 |
| US20190262327A1 (en) | 2016-03-15 | 2019-08-29 | Astrazeneca Ab | Combination of a bace inhibitor and an antibody or antigen-binding fragment for the treatment of a disorder associated with the accumulation of amyloid beta |
| AR107783A1 (es) | 2016-03-15 | 2018-06-06 | Lilly Co Eli | Terapia de combinación |
| WO2017169503A1 (ja) * | 2016-04-01 | 2017-10-05 | 国立大学法人 千葉大学 | 含窒素芳香族アミドの製造方法、ピロール・イミダゾールポリアミドの製造方法、及び化合物 |
| CN107892697B (zh) | 2016-12-26 | 2020-11-03 | 郑州泰基鸿诺医药股份有限公司 | 一种[1,3]噻嗪-2-胺类化合物及应用，药物组合物 |
| CN107954927A (zh) * | 2017-10-30 | 2018-04-24 | 广东莱佛士制药技术有限公司 | 一种3-溴-5-(丙炔-1-基)吡啶的制备方法 |
| WO2019122268A1 (en) | 2017-12-21 | 2019-06-27 | Astrazeneca Ab | Processes for the stereoselective preparation of bace inhibitors |
| WO2019122421A1 (en) | 2017-12-22 | 2019-06-27 | Astrazeneca Ab | Stereoselective ketone reduction using a ketoreductase enzyme |
| WO2019129750A1 (en) | 2017-12-29 | 2019-07-04 | Astrazeneca Ab | Processes for the racemization of dihydroimidazole ring systems |
| WO2019129755A1 (en) | 2017-12-29 | 2019-07-04 | Astrazeneca Ab | Ketal hydrogenation |
| CN110615751B (zh) * | 2018-06-19 | 2021-08-17 | 上海医药工业研究院 | 一种2-氧代硫代丙酰胺的制备方法 |
| JP2022525157A (ja) | 2019-03-14 | 2022-05-11 | アストラゼネカ・アクチエボラーグ | 体重減少のためのラナベセスタット |
| CN111253427A (zh) * | 2020-03-13 | 2020-06-09 | 苏州大学 | 正丁基锂在催化醛和硅烷的氰硅化反应中的应用 |
| CN114989103B (zh) * | 2022-06-09 | 2024-07-09 | 杭州科巢生物科技有限公司 | 一种2-甲氧基-3-(1-甲基-1h-1,2,4-三唑-3-基)苯胺的制备方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100452491B1 (ko) | 2001-03-29 | 2004-10-12 | 한미약품 주식회사 | 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법 |
| WO2002098462A1 (en) * | 2001-06-01 | 2002-12-12 | Ono Pharmaceutical Co., Ltd. | Remedies containing aldose reductase inhibitor as the active ingredient for demyelinating diseases or diseases associated with demyelination |
| US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7915424B2 (en) | 2004-03-22 | 2011-03-29 | Eli Lilly And Company | Pyridyl derivatives and their use as mGlu5 antagonists |
| MX2007016180A (es) | 2005-06-14 | 2008-03-07 | Schering Corp | Inhibidores de aspartil proteasas. |
| JP2009520686A (ja) | 2005-11-21 | 2009-05-28 | アストラゼネカ・アクチエボラーグ | 新規な２−アミノ−イミダゾール−４−オン化合物並びに認知障害、アルツハイマー病、神経変性及び認知症の治療に使用する医薬の製造におけるその使用 |
| CA2633992A1 (en) | 2005-12-21 | 2007-07-05 | Boehringer Ingelheim International Gmbh | Pyrimidine derivatives useful as inhibitors of pkc-theta |
| WO2007100536A1 (en) | 2006-02-24 | 2007-09-07 | Wyeth | DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE |
| CN101506162B (zh) * | 2006-06-22 | 2012-06-27 | 阿斯利康(瑞典)有限公司 | 作为β位淀粉样前体蛋白裂解酶抑制剂的取代的异吲哚和它们的用途 |
| WO2008076044A1 (en) * | 2006-12-20 | 2008-06-26 | Astrazeneca Ab | Novel 2-amino-5, 5-diaryl-imidazol-4-ones |
| EP2108018A2 (en) * | 2007-02-01 | 2009-10-14 | Glaxo Group Limited | 8-oxa-1,4-diazaspiro [4,5] dec-3-en-1-yl and 1,4,8-triazaspiro [4,5] dec-3-en-1-yl acetamides as glyti transporter inhibitors in treatment of neurological and neuropsychiatric disorders |
| AU2008248129B8 (en) * | 2007-05-07 | 2013-05-30 | Merck Sharp & Dohme Corp. | Gamma secretase modulators |
| WO2009100169A1 (en) | 2008-02-06 | 2009-08-13 | Glaxo Group Limited | Dual pharmacophores - pde4-muscarinic antagonistics |
| FR2929943B1 (fr) | 2008-04-15 | 2010-09-24 | Inst Rech Developpement Ird | Sels de quinoleines 2-substituees |
| EP2318416B1 (en) | 2008-07-28 | 2013-09-04 | Eisai R&D Management Co., Ltd. | Spiroaminodihydrothiazine derivatives |
| US8450308B2 (en) | 2008-08-19 | 2013-05-28 | Vitae Pharmaceuticals, Inc. | Inhibitors of beta-secretase |
| CA2736130C (en) | 2008-09-11 | 2014-01-14 | Amgen Inc. | Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use |
| CA2753730C (en) * | 2009-03-13 | 2020-12-22 | Vitae Pharmaceuticals, Inc. | Inhibitors of beta-secretase |
| TW201103893A (en) | 2009-07-02 | 2011-02-01 | Astrazeneca Ab | New compounds |
| TW201105650A (en) | 2009-07-02 | 2011-02-16 | Astrazeneca Ab | New compounds |
| CN102812005B (zh) | 2010-02-24 | 2014-12-10 | 生命医药公司 | β-分泌酶抑制剂 |
| US20120065195A1 (en) | 2010-03-31 | 2012-03-15 | Clark Christopher T | Compounds for treating neurodegenerative diseases |
| WO2011130741A1 (en) | 2010-04-16 | 2011-10-20 | Array Biopharma Inc. | Compounds for treating neurodegenerative diseases |
| WO2012019056A1 (en) | 2010-08-05 | 2012-02-09 | Amgen Inc. | Amino-iso-indole, amino-aza-iso-indole, amino-dihydroisoquinoline and amino-benzoxazine compounds as beta-secretase modulators and methods of use |
| US20120083501A1 (en) | 2010-09-24 | 2012-04-05 | Hunt Kevin W | Compounds for treating neurodegenerative diseases |
| WO2012071458A1 (en) | 2010-11-22 | 2012-05-31 | Array Biopharma Inc. | Heterocyclic inhibitors of beta - secretase for the treatment of neurodegenerative diseases |
| US8415483B2 (en) * | 2010-12-22 | 2013-04-09 | Astrazeneca Ab | Compounds and their use as BACE inhibitors |
| EP2780321B1 (en) | 2011-10-10 | 2015-12-30 | Astrazeneca AB | Mono-fluoro beta-secretase inhibitors |
| US9000182B2 (en) * | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | 2H-imidazol-4-amine compounds and their use as BACE inhibitors |
| US9000184B2 (en) * | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors |
| US9000185B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cycloalkyl ether compounds and their use as BACE inhibitors |
| US9000183B2 (en) * | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors |
| US10548882B2 (en) | 2012-06-21 | 2020-02-04 | Astrazeneca Ab | Camsylate salt |
-
2011
- 2011-12-20 US US13/331,284 patent/US8415483B2/en active Active
- 2011-12-21 SG SG2013045323A patent/SG191127A1/en unknown
- 2011-12-21 CA CA2822378A patent/CA2822378C/en active Active
- 2011-12-21 JP JP2013546075A patent/JP6180325B2/ja active Active
- 2011-12-21 SI SI201131195A patent/SI2655378T1/sl unknown
- 2011-12-21 RS RS20170483A patent/RS55961B1/sr unknown
- 2011-12-21 PT PT118502327T patent/PT2655378T/pt unknown
- 2011-12-21 TW TW100147843A patent/TWI618700B/zh not_active IP Right Cessation
- 2011-12-21 SM SM20170243T patent/SMT201700243T1/it unknown
- 2011-12-21 PH PH1/2017/500851A patent/PH12017500851A1/en unknown
- 2011-12-21 AU AU2011345389A patent/AU2011345389B2/en active Active
- 2011-12-21 CN CN201180068285.7A patent/CN103380133B/zh active Active
- 2011-12-21 EP EP11850232.7A patent/EP2655378B1/en active Active
- 2011-12-21 PE PE2013001452A patent/PE20141191A1/es active IP Right Grant
- 2011-12-21 HR HRP20170723TT patent/HRP20170723T1/hr unknown
- 2011-12-21 WO PCT/SE2011/051555 patent/WO2012087237A1/en not_active Ceased
- 2011-12-21 BR BR112013016030-6A patent/BR112013016030B1/pt active IP Right Grant
- 2011-12-21 HU HUE11850232A patent/HUE033274T2/en unknown
- 2011-12-21 EP EP17150757.7A patent/EP3176172B1/en active Active
- 2011-12-21 TW TW105141254A patent/TWI633092B/zh not_active IP Right Cessation
- 2011-12-21 EA EA201690787A patent/EA032687B1/ru not_active IP Right Cessation
- 2011-12-21 DK DK11850232.7T patent/DK2655378T3/en active
- 2011-12-21 KR KR1020137019193A patent/KR101916975B1/ko active Active
- 2011-12-21 NZ NZ709235A patent/NZ709235A/en not_active IP Right Cessation
- 2011-12-21 ME MEP-2017-115A patent/ME02728B/me unknown
- 2011-12-21 NZ NZ612041A patent/NZ612041A/en not_active IP Right Cessation
- 2011-12-21 PL PL11850232T patent/PL2655378T3/pl unknown
- 2011-12-21 EA EA201390830A patent/EA025746B9/ru not_active IP Right Cessation
- 2011-12-21 MX MX2013007319A patent/MX342477B/es active IP Right Grant
- 2011-12-21 CN CN201610341918.1A patent/CN106008355B/zh active Active
- 2011-12-21 SG SG10201602241SA patent/SG10201602241SA/en unknown
- 2011-12-21 MY MYPI2013701047A patent/MY178156A/en unknown
- 2011-12-21 PE PE2017001273A patent/PE20171342A1/es unknown
- 2011-12-21 ES ES17150757T patent/ES2780928T3/es active Active
- 2011-12-21 PH PH1/2013/501313A patent/PH12013501313A1/en unknown
- 2011-12-21 ES ES11850232.7T patent/ES2626727T3/es active Active
- 2011-12-21 LT LTEP11850232.7T patent/LT2655378T/lt unknown
- 2011-12-22 UY UY0001033829A patent/UY33829A/es not_active Application Discontinuation
- 2011-12-22 AR ARP110104899A patent/AR084553A1/es not_active Application Discontinuation
- 2011-12-24 SA SA114360153A patent/SA114360153B1/ar unknown
- 2011-12-24 SA SA111330107A patent/SA111330107B1/ar unknown
-
2013
- 2013-03-15 US US13/833,221 patent/US8865911B2/en active Active
- 2013-06-20 NI NI201300055A patent/NI201300055A/es unknown
- 2013-06-20 GT GT201300165A patent/GT201300165A/es unknown
- 2013-06-20 DO DO2013000147A patent/DOP2013000147A/es unknown
- 2013-06-21 CR CR20130308A patent/CR20130308A/es unknown
- 2013-06-21 CL CL2013001849A patent/CL2013001849A1/es unknown
- 2013-06-21 CO CO13148240A patent/CO6781485A2/es active IP Right Grant
- 2013-06-21 EC ECSP13012708 patent/ECSP13012708A/es unknown
- 2013-07-19 ZA ZA2013/05495A patent/ZA201305495B/en unknown
-
2014
- 2014-09-15 US US14/486,959 patent/US9248129B2/en not_active Expired - Fee Related
-
2015
- 2015-12-22 US US14/978,756 patent/US20160184303A1/en not_active Abandoned
-
2016
- 2016-01-29 AU AU2016200538A patent/AU2016200538B2/en not_active Ceased
- 2016-07-25 DO DO2016000191A patent/DOP2016000191A/es unknown
- 2016-07-29 JP JP2016149234A patent/JP6333317B2/ja active Active
-
2017
- 2017-01-31 DO DO2017000030A patent/DOP2017000030A/es unknown
- 2017-05-31 CY CY20171100566T patent/CY1119211T1/el unknown
- 2017-07-26 US US15/659,816 patent/US9918985B2/en not_active Expired - Fee Related
- 2017-11-14 AU AU2017261475A patent/AU2017261475A1/en not_active Abandoned
-
2018
- 2018-01-26 JP JP2018011088A patent/JP6527255B2/ja not_active Expired - Fee Related
- 2018-01-31 US US15/884,752 patent/US10231967B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014504300A5 (https=) | ||
| AU2020271838B2 (en) | Pyrimidinone derivatives as SHP2 antagonists | |
| CN113874363B (zh) | 蛋白质酪氨酸磷酸酶抑制剂 | |
| NZ612041A (en) | Compounds and their use as bace inhibitors | |
| CA3007412C (en) | The use of 1,4-disubstituted pyridazine compounds to treat huntington's disease | |
| TWI583678B (zh) | 新穎雙環二氫異喹啉－１－酮衍生物 | |
| AU2005304560B2 (en) | Lactam compounds and their use as pharmaceuticals | |
| HRP20240994T1 (hr) | Spoj inhibitora jak i njegova uporaba | |
| IL310992A (en) | NLRP3 inhibitors | |
| JP5511793B2 (ja) | 新規な置換インドリン−２−オン誘導体およびｐ３８マイトジェン活性化タンパク質キナーゼ阻害剤としてのそれらの使用 | |
| FI4065575T3 (fi) | Substituoituja trisyklisiä yhdisteitä | |
| JP2012532931A5 (https=) | ||
| JP2022500402A5 (https=) | ||
| TW201625617A (zh) | 作為ｍｄｍ２－ｐ５３抑制劑之新穎螺－［３ｈ－吲哚－３，２’－吡咯啶］－２（１ｈ）－酮化合物及其衍生物 | |
| RU2016140338A (ru) | Азаспиро производные в качестве антагонистов trpm8 | |
| JP2018505880A (ja) | がんの治療のための化合物 | |
| JP2013500972A (ja) | Ｓｙｋキナーゼ阻害剤としての２，７−ナフチリジン−１−オン誘導体 | |
| TW201333012A (zh) | 咪唑并吡咯啶酮化合物 | |
| HRP20200098T1 (hr) | Spirociklični spojevi kao inhibitori triptofan hidroksilaze | |
| JP2019530725A5 (https=) | ||
| RS53490B1 (sr) | Derivati tetrahidro-pirido-pirimidina | |
| JP2021505598A (ja) | 心不全およびそれに関連する障害の治療または予防に有用なβ−３アドレナリン受容体のモジュレーター | |
| JP2017516830A (ja) | ピラゾール化合物及びｔ型カルシウムチャンネルブロッカーとしてのそれらの使用 | |
| WO2017157792A1 (en) | Combinations of copanlisib | |
| JP2014528436A5 (https=) |